A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)
Titel:
A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)
Auteur:
Paplomata, E. Bachelot, T. Mueller, V. Murias, C. Murthy, R.K. Okines, A.F.C. Wardley, A.M. Walker, L.N. Antunes De Melo e Oliveira, A.M.